OBJECTIVE: To study the antitumor activity of Huanglian Jiedu decoction (HLJDT). METHOD: Antitumor activities were tested in mice with experimental tumor H22 in vivo, and the thymus index, spleen index and tumor inhibitory rate were evaluated. The effects on cancer cells from human were investigated in vitro using serum pharmacological approach. Swille, SPC-A-1, SGC-7901 and MCF-7 cancer cells were incubated in culture media containing serum from mice medicated with HLJDT. The inhibitory effects of HLJDT serum were observed by MTT assay. RESULT: HLJDT showed significant antitumor activities on H22 in mice. All of the HLJDT serum in different dosage groups could highly inhibit the proliferation of 4 cancer cell lines from human. CONCLUSION: The HLJDT can significantly inhibit the tumor H22 in mice in a dose-dependent manner, the drug serum has obvious anticancer effects against Swille, SPC-A-1, SGC-7901 and MCF-7.
OBJECTIVE: To study the antitumor activity of Huanglian Jiedu decoction (HLJDT). METHOD: Antitumor activities were tested in mice with experimental tumor H22 in vivo, and the thymus index, spleen index and tumor inhibitory rate were evaluated. The effects on cancer cells from human were investigated in vitro using serum pharmacological approach. Swille, SPC-A-1, SGC-7901 and MCF-7 cancer cells were incubated in culture media containing serum from mice medicated with HLJDT. The inhibitory effects of HLJDT serum were observed by MTT assay. RESULT: HLJDT showed significant antitumor activities on H22 in mice. All of the HLJDT serum in different dosage groups could highly inhibit the proliferation of 4 cancer cell lines from human. CONCLUSION: The HLJDT can significantly inhibit the tumor H22 in mice in a dose-dependent manner, the drug serum has obvious anticancer effects against Swille, SPC-A-1, SGC-7901 and MCF-7.